Země: Velká Británie
Jazyk: angličtina
Zdroj: MHRA (Medicines & Healthcare Products Regulatory Agency)
Clindamycin phosphate
Bowmed Ibisqus Ltd
J01FF01
Clindamycin phosphate
150mg/1ml
Solution for injection
Intravenous; Intramuscular
No Controlled Drug Status
Valid as a prescribable product
BNF: 05010600; GTIN: 5060130130300 5060130130447
Realized by: QUALITY SYSTEM - ISO 9001:2008 ARTWORK PDF 1.5 ISSUE DATE 20/06/2014 OPERATOR RI006M DRAFT 03 SEPARATIONS: (BLACK) MEAS. (mm): 210 X 297(FOLD 150X36 MM) CUTTING PROFILE: ACSI003 TECHNICAL SPECIF.: ACSI001L00 g/sq.mt: 60 GR/M 2 Thikness: 0,065 MM FONT TYPE: MYRIAD PRO Size: 8 PT THIS ARTWORK IS PROPERTY OF: FACTA/ACS DOBFAR CLIENT APPROVAL DATE SIGNATURE PRODUCT NAME: I-CLINDAMYCINA 150MG/ML SOLUTION FOR INJECTION PRODUCT CODE: L08GBCLIN06 EURPACK GRAFIFARMA GRAFIFLEX - Aprilia (LT) tel. +39 06 92732420 produzione@grafifarma.it - Robecco s/N (MI) tel. +39 02 94974002 milano@grafifarma.it 10 mm 20 30 40 50 60 70 80 90 Ricordiamo che il risultato cromatico delle stampe potrà essere diverso in funzione del supporto e della tecnica utilizzata. We remind you that prints chromatic results could be different depending on support and used technique. - La responsabilità della EURPACK GRAFIFARMA GRAFIFLEX Srl, termina con l’approvazione del seguente documento. EURPACK GRAFIFARMA GRAFIFLEX’s responsability ends with the approval of the present document. - Vietato l’utilizzo del presente tassello di informazioni se non espressamente autorizzato dalla EURPACK GRAFIFARMA GRAFIFLEX Srl. It is forbidden the use of the present information if not officially allowed from EURPACK GRAFIFARMA GRAFIFLEX Srl. v.01-2013 PACKAGE LEAFLET: INFORMATION FOR THE USER CLINDAMYCIN 150MG/ML, SOLUTION FOR INJECTION _CLINDAMYCIN PHOSPHATE_ READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. �������������������������������������������������� ������������������������������������������������������������������������ ���������������������������������������������������� Přečtěte si celý dokument
OBJECT 1 CLINDAMYCIN 300MG/2ML SOLUTION FOR INJECTION AMPOULES (150MG/ML IN 2ML AMPOULES) Summary of Product Characteristics Updated 21-Dec-2017 | Bowmed Ibisqus Limited 1. Name of the medicinal product Clindamycin 150mg/ml, solution for injection 2. Qualitative and quantitative composition Each ml of solution contains clindamycin phosphate equivalent to 150 mg clindamycin. For a full list of excipients, see section 6.1. 3. Pharmaceutical form Solution for Injection. Clear, colourless, sterile solution. 4. Clinical particulars 4.1 Therapeutic indications Antibacterial. Serious infections caused by susceptible Gram-positive organisms, staphylococci (both penicillinase- and non-penicillinase-producing), streptococci (except _Streptococcus faecalis_) and pneumococci. It is also indicated in serious infections caused by susceptible anaerobic pathogens such as _Bacteroides_ spp, _Fusobacterium_ spp, _Propionibacterium_ spp, _Peptostreptococcus_ spp. and microaerophilic streptococci. Clindamycin does not penetrate the blood/brain barrier in therapeutically effective quantities. Consideration should be given to official guidance on the appropriate use of antibacterial agents including national and local guidelines 4.2 Posology and method of administration Routes of administration: Intramuscular injection Intravenous infusion Adults: Serious infections: 600 mg - 1.2 g/day in two, three or four equal doses. More severe infections: 1.2 - 2.7 g/day in two, three or four equal doses. Single i.m. injections of greater than 600 mg are not recommended nor is administration of more than 1.2 g in a single one hour infusion. For more serious infections, these doses may have to be increased. In life-threatening situations, doses as high as 4.8 g daily have been given intravenously to adults. Alternatively, the drug may be administered in the form of a single rapid infusion of the first dose followed by continuous IV. infusion. Renal and/or hepatic insufficiency The dosage may require reduction in patients with renal and/or hepatic Přečtěte si celý dokument